Kineret launches in the UK following clinician consultation

11 July 2018

After its European Medicines Agency (EMA) approval in this indication in April, Swedish Orphan Biovitrum's (STO: SOBI) Kineret (anakinra) has launched in the UK for the treatment of adult onset Still's disease (AOSD) and systemic-onset juvenile idiopathic arthritis (SOJIA).

Kineret, a protein which first entered use in the USA in 2001, was already available in the UK for rheumatoid arthritis and cryopyrin-associated period syndromes. This label extension is based on analyses of around 400 patients with AOSD and early onset Still's disease, which are genetically similar to SOJIA.

Commenting on the launch of Kineret, clinical immunology and allergy consultant at St James Hospital Leeds, Sisina Sabvic, said: "This is an important step in providing additional therapeutic options for the UK Still’s patients, especially for those who have not responded to previous treatments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK